MAZE
Maze Therapeutics·NASDAQ
--
--(--)
--
--(--)
MAZE fundamentals
During Q3 2025, Maze Therapeutics (MAZE) reported revenue of --, a YoY change of 0.00%. Net income was -30.09M, a YoY change of -21.55%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | TTM |
|---|
Start Date | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | -- |
End Date | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | 165.00M -- | 2.50M -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Sales and Services Revenue | 0 -- | -- -- | 165.00M -- | 2.50M -- | 0 -- | -- -- | 0 -100.00% | 0 -100.00% | -- -- |
Operating Expenses | 23.05M -- | 28.01M -- | 25.45M -- | 26.73M -- | 29.73M +28.96% | 35.40M +26.37% | 36.47M +43.34% | 32.97M +23.33% | 134.57M -- |
Selling, General and Administrative Expenses | 7.01M -- | 6.14M -- | 5.90M -- | 6.87M -- | 7.51M +7.19% | 7.82M +27.44% | 8.37M +41.82% | 7.78M +13.14% | 31.47M -- |
General and Administrative Expenses | 7.01M -- | 6.14M -- | 5.90M -- | 6.87M -- | 7.51M +7.19% | 7.82M +27.44% | 8.37M +41.82% | 7.78M +13.14% | 31.47M -- |
Research and Development Expenses | 16.05M -- | 21.88M -- | 19.55M -- | 19.86M -- | 22.22M +38.46% | 27.58M +26.07% | 28.11M +43.80% | 25.19M +26.86% | 103.09M -- |
Operating Income | -23.05M -- | -28.01M -- | 139.56M -- | -24.23M -- | -29.73M -28.96% | -35.40M -26.37% | -36.47M -126.14% | -32.97M -36.06% | -134.57M -- |
Non-Operating Income (Loss) | -3.53M -- | -4.48M -- | 1.23M -- | -802.00K -- | -128.00K +96.37% | 2.62M +158.37% | 2.79M +127.79% | 2.88M +458.85% | 8.16M -- |
Gain (Loss) on Change in Fair Value | -3.83M -- | -4.76M -- | 216.00K -- | -2.65M -- | -1.64M +57.08% | 0 +100.00% | 0 -100.00% | 0 +100.00% | -1.64M -- |
Other Non-Operating Income (Loss) | -1.66M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | -1.97M -- | -281.00K -- | -1.01M -- | -1.85M -- | -1.52M +22.89% | -2.62M -830.60% | -2.79M -176.46% | -2.88M -55.90% | -9.80M -- |
Interest Income | -- -- | -- -- | 1.01M -- | 1.85M -- | -3.14M -- | -- -- | 2.79M +176.46% | 2.88M +55.90% | -- -- |
Pretax Income From Continuing Operations | -26.58M -- | -32.49M -- | 140.78M -- | -25.03M -- | -29.85M -12.33% | -32.79M -0.90% | -33.68M -123.92% | -30.09M -20.20% | -126.41M -- |
Income Tax Expense | -- -- | -- -- | 1.73M -- | -279.00K -- | -275.00K -- | -- -- | -- -- | 0 +100.00% | -- -- |
Net Income | -26.58M -- | -32.49M -- | 139.06M -- | -24.75M -- | -29.58M -11.30% | -32.79M -0.90% | -33.68M -124.22% | -30.09M -21.55% | -126.13M -- |
Net Income Attributable to Owners of the Company | -26.58M -- | -32.49M -- | 139.06M -- | -24.75M -- | -29.58M -11.30% | -32.79M -0.90% | -33.68M -124.22% | -30.09M -21.55% | -126.13M -- |
Preferred Stock Dividends | 0 -- | -- -- | -- -- | -- -- | 14.97M -- | -- -- | -- -- | -- -- | -- -- |
Other Adjustments | 0 -- | -- -- | 124.91M -- | 0 -- | -39.65M -- | -- -- | 0 -100.00% | 0 -- | -- -- |
Net Income Attributable to Common Stockholders | -26.58M -- | -32.49M -- | 14.14M -- | -24.75M -- | -4.91M +81.54% | -32.79M -0.90% | -33.68M -338.12% | -30.09M -21.55% | -101.46M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 69.00K -- | -- -- |
Total Comprehensive Income | -26.58M -- | -32.49M -- | 139.06M -- | -24.75M -- | -29.58M -11.30% | -32.79M -0.90% | -33.68M -124.22% | -30.02M -21.28% | -126.06M -- |
Total Comprehensive Income Attributable to Owners of the Company | 73.84M -- | -- -- | 139.06M -- | -24.75M -- | -81.81M -210.80% | -- -- | -33.68M -124.22% | -30.02M -21.28% | -- -- |
Basic EPS | -- -- | -13.91 -- | 5.92 -- | -10.25 -- | -- -- | -1.15 +91.73% | -0.77 -113.01% | -0.66 +93.56% | -- -- |
Basic EPS from Continuing Operations | -- -- | -13.91 -- | 5.92 -- | -10.25 -- | -- -- | -1.15 +91.73% | -0.77 -113.01% | -0.66 +93.56% | -- -- |
Diluted EPS | -- -- | -13.91 -- | 3.22 -- | -10.25 -- | -- -- | -1.15 +91.73% | -0.77 -123.91% | -0.66 +93.56% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -13.91 -- | 3.22 -- | -10.25 -- | -- -- | -1.15 +91.73% | -0.77 -123.91% | -0.66 +93.56% | -- -- |
You can ask Aime
What does Maze Therapeutics do and what are its main business segments?Did Maze Therapeutics beat or miss consensus estimates last quarter?What is Maze Therapeutics's latest dividend and current dividend yield?What were the key takeaways from Maze Therapeutics's earnings call?What guidance did Maze Therapeutics's management provide for the next earnings period?What is the revenue and EPS growth rate for Maze Therapeutics year over year?What factors drove the changes in Maze Therapeutics's revenue and profit?What is Maze Therapeutics's gross profit margin?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
